Search

Your search keyword '"Taszner M"' showing total 5 results
Start Over Author "Taszner M" Journal hematological oncology
5 results on '"Taszner M"'

1. ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) GRADE 1–3A: RESULTS FROM A PRESPECIFIED ANALYSIS OF THE PIVOTAL PHASE II STUDY ELM‐2

Author

Novelli, S., primary, Luminari, S., additional, Taszner, M., additional, Cho, S., additional, Le Gouill, S., additional, Poon, M., additional, Villasboas, J. C., additional, Champion, R., additional, Bachy, E., additional, Guidez, S., additional, Alonso, A., additional, Jagadeesh, D., additional, Merli, M., additional, Tucker, D., additional, Cai, J., additional, Leite de Oliveira, C., additional, Zhu, M., additional, Chaudhry, A., additional, Mohamed, H., additional, Ambati, S., additional, and Kim, T. M., additional

Published
2023
Full Text
View/download PDF

2. Outpatient treatment with 2 cycles of Bendamustine, Gemcitabine and Dexamethasone is Effective and Safe in r/r Hodgkin Lymphoma—Polish Lymphoma Research Group Study

Author

Paszkiewicz‐Kozik, E., primary, Kurlapski, M., additional, Swoboda, R., additional, Subocz, E., additional, Szymanski, M., additional, Taszner, M., additional, Wicherska‐Pawlowska, K., additional, Koclega, A., additional, Domanska‐Czyz, K., additional, Swierkowska, M., additional, Woszczyk, D., additional, Targonski, L., additional, Chmielowska, E., additional, Dabrowska‐Iwanicka, A., additional, Ostrowska, B., additional, Romejko‐Jarosinska, J., additional, Kotarska, M., additional, Druzd‐Sitek, A., additional, Konecki, R., additional, Mroz‐Zycinska, E., additional, Poplawska, L., additional, Borawska, A., additional, Rybka, J., additional, Michalski, W., additional, Rybski, S., additional, Halka, J., additional, Czyz, A., additional, Giebel, S., additional, Walewski, J., additional, and Zaucha, J., additional

Published
2023
Full Text
View/download PDF

3. OFATUMUMAB WITH IVAC FOR DLBCL PATIENTS WHO FAILED R-CHOP AND WERE NOT CANDIDATES FOR HIGH-DOSE THERAPY AND ASCT - PHASE 2 TRIAL OF THE POLISH LYMPHOMA RESEARCH GROUP (PLRG-8)

Author

Paszkiewicz-Kozik, E., primary, Michalski, W., additional, Taszner, M., additional, Knopińska-Posłuszny, W., additional, Mordak-Domagała, M., additional, Najda, J., additional, Borawska, A., additional, Romejko-Jarosińska, J., additional, Chełstowska, M., additional, Świerkowska, M., additional, Dąbrowska-Iwanicka, A., additional, Malenda, A., additional, Druzd-Sitek, A., additional, Konecki, R., additional, Kuniega, B., additional, Osowiecki, M., additional, Ostrowska, B., additional, Szpila, T., additional, Domańska-Czyż, K., additional, Szymański, M., additional, Targoński, Ł., additional, Poplawska, L., additional, Kotarska, M., additional, Giebel, S., additional, Lange, A., additional, Pluta, A., additional, Warzocha, K., additional, Zaucha, J., additional, Rymkiewicz, G., additional, and Walewski, J., additional

Published
2019
Full Text
View/download PDF

4. TRIAL IN PROGRESS: ODRONEXTAMAB, A CD20×CD3 BISPECIFIC ANTIBODY, FOR THE TREATMENT OF RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA (R/R MZL)—A COHORT FROM THE ELM‐2 STUDY.

Author

Cho, S., Kim, T. M., Taszner, M., Chen, T. Y., Chaudhry, A., Ufkin, M., Uppala, A., Sabir, A., Mohamed, H., Ambati, S., and Bachy, E.

Subjects
MUCOSA-associated lymphoid tissue lymphoma, BISPECIFIC antibodies
Abstract

The MZL cohort is planned to include 78 patients, who will receive IV odronextamab monotherapy until disease progression or other protocol-defined reason for treatment discontinuation. In the Phase 1 ELM-1 study, odronextamab monotherapy showed antitumor activity and a manageable safety profile in a range of I R i / I R i B-NHL subtypes, including MZL ( I n i = 6; ORR 67%) (Bannerji et al. B Introduction: b MZL is a heterogeneous disease comprising 3 subtypes, extra-nodal MZL of mucosa-associated lymphoid tissue, nodal MZL, and splenic MZL. [Extracted from the article]

Published
2023
Full Text
View/download PDF

5. AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL). REAL‐WORLD REPORT OF POLISH LYMPHOMA RESEARCH GROUP.

Author

Ostrowska, B., Domanska‐Czyz, K., Giza, A., Taszner, M., Romejko‐Jarosinska, J., Targonski, L., Poplawska, L., Konecki, R., Kotarska, M., Szymanski, M., Borawska, A., Swierkowska, M., Dabrowska‐Iwanicka, A., Druzd‐Sitek, A., Paszkiewicz‐Kozik, E., Mroz‐Zycinska, E., Osowiecki, M., Zimowska‐Curylo, D., Owczarek‐Kaczmarek, J., and Tajer, J.

Subjects
STEM cell transplantation, HEMATOPOIETIC stem cell transplantation, CENTRAL nervous system, RESEARCH teams, LYMPHOMAS
Abstract

B Conclusion: b HDC-ASCT based on conditioning regimen consisted of carmustine, etoposide and thiotepa (BET) is a relatively safe and highly effective treatment for PCNSL patients. B Introduction: b High-dose chemotherapy with autologous stem-cell transplantation (HDC-ASCT) is now the preferred consolidation strategy for young PCNSL patients. At the end of induction 29 (64.5%) patients obtained CR/CRun (19/10 respectively), with additional 5 (11%) patients with no evidence of disease at baseline, and 11 (24.5%) in PR, based on standard CT/MRI assessment. [Extracted from the article]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results